Effect of sublingual immunotherapy on clinical and laboratory autoimmunity

There still are few data on the long-term safety of sublingual immunotherapy (SLIT). The aim of this study was to assess the appearance of autoimmune diseases in patients before and after SLIT. New cases of autoimmune diseases were monitored. Patients in the SLIT group (n = 816) were compared with c...

Full description

Saved in:
Bibliographic Details
Published inImmunotherapy Vol. 16; no. 4; p. 235
Main Authors Bozek, Andrzej, Mućka, Szymon, Miodonska, Martyna, Zlik, Anna, Mroz-Dybowska, Magdalena
Format Journal Article
LanguageEnglish
Published England 01.03.2024
Subjects
Allergens
Autoimmune Diseases - therapy
Autoimmunity
Humans
Sublingual Immunotherapy
Treatment Outcome
allergy
sublingual immunotherapy
autoimmune
lupus
IgE
psoriasis
Online AccessGet more information

Cover

More Information
Summary:There still are few data on the long-term safety of sublingual immunotherapy (SLIT). The aim of this study was to assess the appearance of autoimmune diseases in patients before and after SLIT. New cases of autoimmune diseases were monitored. Patients in the SLIT group (n = 816) were compared with controls (n = 1096). The new incidences of autoimmune diseases in the SLIT group were lower compared with the control group: 18 (2.2%) versus 58 (5.3%); p < 0.05. Systemic lupus erythematosus, psoriasis and Hashimoto appeared much more often in the control group. SLIT had no significant effect on the induction of autoimmune diseases.
ISSN:1750-7448
DOI:10.2217/imt-2023-0231